Heart tissue cells

Heart tissue cells represent the collective cellular components of the heart, including cardiomyocytes, fibroblasts, endothelial cells, and specialized conduction cells like Purkinje fibers. Cardiomyocytes are the primary functional units, responsible for the myogenic contraction that drives blood throughout the circulatory system via a process known as excitation-contraction coupling [StatPearls, 2023]. While these cells are the site of action for many cardiovascular medications, the term heart tissue cells is a biological descriptor of a tissue type rather than a specific molecular therapeutic target such as a receptor or enzyme. Pathological conditions such as myocardial infarction, heart failure, and various arrhythmias arise from dysfunction within these cells, often involving impaired calcium handling, oxidative stress, or structural remodeling [NIH, 2022]. Pharmacological intervention typically involves targeting specific proteins located on or within these cells, such as beta-adrenergic receptors or voltage-gated ion channels, to restore hemodynamic stability [PubChem, 2024]. Monitoring cardiac-specific biomarkers like Troponin and BNP is the clinical standard for assessing cellular damage and the efficacy of treatments targeting heart tissue [Mayo Clinic, 2023].

Other names

Cardiac cellsMyocardiumCardiomyocytesCardiac myocytesHeart muscle cellsCardiac fibroblasts

Drugs do not target the cells as a whole but rather specific molecular entities within them, such as ion channels (sodium, potassium, calcium), adrenergic receptors, and enzymes to modulate cardiac contractility, heart rate, and electrical stability [StatPearls, 2023].